Long-term follow-up after tight control of blood pressure in type 2 diabetes

Holman, Rury R., Paul, Sanjoy K., Bethel, M. Angelyn, Neil, H. Andrew W., Matthews, David R.·2008·New England Journal of Medicine
DOI 10.1056/nejmoa0806359

Cited by (761)

Items 301–400 of 761

  1. Prevalence of referable, sight-threatening retinopathy in type 1 diabetes and its relationship to diabetes duration and systemic risk factors
    Alasdair Warwick, A P Brooks, Clive Osmond, Radhika Krishnan · 2017 · Eye
  2. High-risk Diabetic Patients in Medicare Part D Programs: Are They Getting the Recommended ACEI/ARB Therapy?
    Yi Yang, Vennela Thumula, Patrick F. Pace, Benjamin F. Banahan, Noel E. Wilkin, William B. Lobb · 2010 · Journal of General Internal Medicine
  3. Complicações macrovasculares do diabetes melito: peculiaridades clínicas, de diagnóstico e manejo
    Cristina Bergmann Triches, Beatriz D'Agord Schaan, Jorge Luiz Gross, Mirela Jobim de Azevedo · 2009 · Arquivos Brasileiros de Endocrinologia & Metabologia
  4. Blood Pressure Trajectories Prior to Death in Patients With Diabetes
    Mary A.M. Rogers, Kathleen Ward, Tanya R. Gure, Hae Mi Choe, Pearl Lee, Steven J. Bernstein, Caroline S. Blaum · 2011 · Diabetes Care
  5. Therapeutic Inertia: Still a Long Way to Go That Cannot Be Postponed
    Manel Mata‐Cases, Josep Franch‐Nadal, Mónica Gratacòs, Dı́dac Mauricio · 2020 · Diabetes Spectrum
  6. Expert consensus on management of diabetic patients with impairment of renal function
    Fabrice Bonnet, E. Gauthier, Henri Gin, Samy Hadjadj, J.-M. Halimi, Thierry P. Hannedouche, Vincent Rigalleau, Dorothée Romand, Ronan Roussel, Philippe Zaoui · 2011 · Diabetes & Metabolism
  7. Hypertensive subjects with type-2 diabetes, the sympathetic nervous system, and treatment implications
    Andrew J.S. Coats, John Malcolm Cruickshank · 2014 · International Journal of Cardiology
  8. Mechanisms of Diabetic Nephropathy – Old Buddies and Newcomers Part 1
    Peter P. Nawroth, Berend Isermann · 2010 · Experimental and Clinical Endocrinology & Diabetes
  9. ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH.
    Ali Abbas Rizvi · 2017 · PubMed
  10. Hyperglycemia, Hypertension, and Dyslipidemia in Type 2 Diabetes Mellitus: Goals for Diabetes Management
    Derek LeRoith · 2008 · Clinical cornerstone
  11. Long-term Effect of Losartan on Kidney Disease in American Indians With Type 2 Diabetes: A Follow-up Analysis of a Randomized Clinical Trial
    Stephanie K. Tanamas, Pierre‐Jean Saulnier, Gudeta D. Fufaa, Kevin M. Wheelock, E. Jennifer Weil, Robert L. Hanson, William C. Knowler, Peter H. Bennett, Robert G. Nelson · 2016 · Diabetes Care
  12. Blood pressure lowering in patients with diabetes—one level might not fit all
    Rhonda M. Cooper‐DeHoff, Eric F. Egelund, Carl J. Pepine · 2010 · Nature Reviews Cardiology
  13. The Legacy Effect in the Prevention of Cardiovascular Disease
    Esther Viñas Esmel, José Naval-Álvarez, Emilio Sacanella · 2020 · Nutrients
  14. Insulin secretion and action affect glucose variability in the early stages of glucose intolerance
    Rumyana B. Dimova, Nevena Y. Chakarova, Giuseppe Daniele, Cristina Bianchi, Angela Dardano, Stefano Del Prato, Tsvetalina I. Tankova · 2022 · Diabetes/Metabolism Research and Reviews
  15. Young-Onset Diabetes in East Asians: From Epidemiology to Precision Medicine
    Juliana C.N. Chan, Chun Kwan O, Andrea O. Y. Luk · 2024 · Endocrinology and Metabolism
  16. Risk for cardiovascular events in an Italian population of patients with type 2 diabetes
    Elisa Pellegrini, Mauro Maurantonio, Iolanda M. Giannico, Marco Simonini, D. Ganazzi, Lucia Carulli, Roberto D’Amico, Andrea Baldini, P. Loria, Marco Bertolotti et al. · 2010 · Nutrition Metabolism and Cardiovascular Diseases
  17. Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes
    Lars Rydén, Grupo de Trabajo de la Sociedad Europea de Cardiología sobre diagnóstico y tratamiento de la cardiopatía isquémica estable, Peter J. Grant, Stefan D. Anker, Christian Berne, Francesco Cosentino, Nicolas Danchin, Christi Deaton, Javier Escaned, Hans Peter Hammes et al. · 2014 · Revista Española de Cardiología
  18. Reducing cardiovascular disease risk in type 2 diabetes: is the focus on glycaemia warranted?
    Lyn D Ferguson, Naveed A. Sattar · 2012 · Diabetes Obesity and Metabolism
  19. Interventions in type 2 diabetes mellitus and cardiovascular mortality–An overview of clinical trials
    Benjamin Burggraaf, Manuel Castro Cabezas · 2017 · European Journal of Internal Medicine
  20. Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
    David Nathanson, Ugne Sabale, Jan W. Eriksson, Thomas Nyström, Anna Norhammar, Urban Olsson, Johan Bodegård · 2017 · PharmacoEconomics - Open
  21. Cluster randomised controlled trial: Educational self-care intervention with older Taiwanese patients with Type 2 diabetes mellitus––Impact on blood glucose levels and diabetic complications
    Ying-Hua Chao, Kim J. Usher, Petra Gertraud Buettner, Colin Adrian Holmes · 2013 · Collegian Journal of the Royal College of Nursing Australia
  22. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs
    Yi Yang, Vennela Thumula, Patrick F. Pace, Benjamin F. Banahan, Noel E. Wilkin, William B. Lobb · 2010 · Journal of the American Pharmacists Association
  23. FT 23, an orally active antifibrotic compound, attenuates structural and functional abnormalities in an experimental model of diabetic cardiomyopathy
    Sih Min Tan, Yuan Zhang, Bing Wang, Christina Y.R. Tan, Steven C. Zammit, Spencer John Williams, Henry Krum, Darren J. Kelly · 2012 · Clinical and Experimental Pharmacology and Physiology
  24. Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003–2008
    Eva Fhärm, Jan Cederholm, Björn Eliasson, Soffia Guðbjörnsdóttir, Olov Rolandsson · 2011 · Diabetic Medicine
  25. A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo–Danish–Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study
    Rebecca K. Simmons, Knut Borch‐Johnsen, Torsten Lauritzen, Guy E.H.M. Rutten, Annelli Sandbæk, Maureen van den Donk, James A Black, Libo Tao, Ed Wilson, Melanie Jane Davies et al. · 2016 · Health Technology Assessment
  26. Understanding and treating hypertension in diabetic populations.
    Massimo Volpe, Allegra Battistoni, Carmine Savoia, Giuliano Tocci · 2015 · PubMed Central
  27. Hypertension and Hypercholesterolemia are Associated with Cataract Development in Patients with Type 2 Diabetes
    Martina Tomić, Romano Vrabec, Petar Raštegorac, Spomenka Ljubić, Tomislav Bulum, Dario Rahelić · 2021 · High Blood Pressure & Cardiovascular Prevention
  28. Current Status of Aggressive Blood Glucose and Blood Pressure Control in Diabetic Hypertensive Subjects
    Steven G. Chrysant, George S. Chrysant · 2011 · The American Journal of Cardiology
  29. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER
    B.W. Karlson, Philip J. Barter, M K Palmer, Pia Lundman, Stephen James Nicholls · 2012 · Nutrition Metabolism and Cardiovascular Diseases
  30. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease
    Swaytha Ganesh, Vinod K. Rustgi · 2016 · Clinics in Liver Disease
  31. Transplantation of human fetal pancreatic progenitor cells ameliorates renal injury in streptozotocin-induced diabetic nephropathy
    Yong-Wei Jiang, Wen-Jian Zhang, Shi-Qing Xu, Hua Lin, Wei-Guo Sui, Honglin Liu, L. Peng, Qing Fang, Li Chen, J. Lou · 2017 · Journal of Translational Medicine
  32. Incremental costs and cost-effectiveness of intensive treatment in individuals with type 2 diabetes detected by screening in the ADDITION-UK trial: An update with empirical trial-based cost data
    M. Laxy, E. Wilson, Clare E. Boothby, S. Griffin · 2017 · Value in Health
  33. Implications of impaired zinc homeostasis in diabetic cardiomyopathy and nephropathy
    Robertina Giacconi, Lu Cai, Laura Costarelli, Maurizio Cardelli, Marco Malavolta, Francesco Piacenza, Mauro Provinciali · 2017 · BioFactors
  34. Prevention of Vascular Complications in Diabetes Mellitus Patients: Focus on the Arterial Wall
    Mojca Lunder, Miodrag Janić, Mišo Šabović · 2018 · Current Vascular Pharmacology
  35. The impact of glucose-lowering therapy on cardiovascular outcomes
    Eberhard Standl, Martin Müller, Oliver Schnell · 2009 · Best Practice & Research Clinical Endocrinology & Metabolism
  36. Diabetes mellitus: Complications, emerging therapeutic targets, and evolving treatment approaches
    Sharfuddin Mohd, Lekkala Lithin Kumar, Vancha Harish, Rakesh Kumar, Aakriti Chaudhary, Vikas Sharma · 2025 · Obesity Medicine
  37. Impact of Delaying Blood Pressure Control in Patients with Type 2 Diabetes: Results of a Decision Analysis
    Neda Laiteerapong, Priya M. John, David O. Meltzer, Elbert S. Huang · 2012 · Journal of General Internal Medicine
  38. Treatment of hypertension in diabetes: what is the best therapeutic option?
    Tonje Amb Aksnes, Sigrid Nordang Skårn, Sverre Erik Kjeldsen · 2012 · Expert Review of Cardiovascular Therapy
  39. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization
    Mark Aagren, Wenli Luo, Elien Moës · 2009 · Journal of Medical Economics
  40. Association of cardiac and non-cardiac chronic disease comorbidity on glycaemic control in a multi-ethnic population with type 1 and type 2 diabetes
    Rajnikant Laxmishanker Mehta, Melanie Jane Davies, S. M. Keramat Ali, Nick A. Taub, Margaret A. Stone, Richard Baker, P.G. McNally, Ian G. Lawrence, Kamlesh K. Khunti · 2011 · Postgraduate Medical Journal
  41. Cumulative in-trial and post-trial effects of blood pressure and lipid lowering
    Yoichiro Hirakawa, Hisatomi Arima, Anthony Rodgers, Mark Woodward, John Philip Chalmers · 2017 · Journal of Hypertension
  42. Predicting diabetes clinical outcomes using longitudinal risk factor trajectories
    György Simon, KEVIN A. PETERSON, M. Regina Castro, Michael S. Steinbach, Vipin Kumar, Pedro J. Caraballo · 2020 · BMC Medical Informatics and Decision Making
  43. Association of obesity with glucose, blood pressure, and lipid goals attainment in patients with concomitant diabetes and hypertension
    Ping Li, Kang Chen, Yi Nie, Lingling Guo, Haibin Wang, Shuang-Shuang Wang, Anping Wang, Dayi Hu, Yiming Mu, Jihu Li et al. · 2015 · Current Medical Research and Opinion
  44. Pharmacological intervention in hypertension using beta-blockers: Real‐world evidence for long-term effectiveness
    Meritxell Sabidó, Thilo Hohenberger, Guido M. Grassi · 2018 · Pharmacological Research
  45. Glucose lowering and cardiovascular disease: what do we know and what should we do?
    ALICE Y.Y. CHENG, Lawrence A. Leiter · 2010 · European Journal of Cardiovascular Prevention & Rehabilitation
  46. The role of β-blockers in the management of hypertension: An Asian perspective
    Brian Tomlinson, Jamshed J Dalal, Jin Huang, L.P. Low, Chang Gyu Park, Abdul Rahman, Eugenio B Reyes, Arieska Ann Soenarta, Anthony Michael Heagerty, Ferenc Folláth · 2011 · Current Medical Research and Opinion
  47. Guidelines for the Primary Prevention of Stroke A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of these guidelines as an educational tool for neurologists. Endorsed by the American Association of Neurological Surgeons, the Congress of Neurological Surgeons, and the Preventive Cardiovascular Nurses Association
    James Frederick Meschia, Cheryl Bushnell, Bernadette M Boden-Albala, Lynne T. Braun, Dawn M. Bravata, Seemant Chaturvedi, Mark A. Creager, Robert H. Eckel, Myriam Fornage, Larry B. Goldstein et al. · 2014
  48. Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes
    Mary T. Korytkowski, Daniel E. Forman · 2017 · Diabetes Care
  49. New Zealand Diabetes Cohort Study cardiovascular risk score for people with Type 2 diabetes: validation in the PREDICT cohort
    Tom Robinson, C. Raina Elley, Sue Wells, Elizabeth Robinson, Timothy W Kenealy, Romana D. Pylypchuk, Dale M. Bramley, Bruce Arroll, Sue M. Crengle, Tania Riddell et al. · 2012 · Journal of Primary Health Care
  50. Quality assessment and improvement in diabetes care—an issue now and for the future
    Zilin Sun · 2010 · Diabetes/Metabolism Research and Reviews
  51. Effect of combined aerobic exercise and resistance training on postmenopausal women with type 2 diabetes: a systematic review and meta-analysis
    Vítor Engrácia Valenti, André dos Santos Chagas, Peter A. Chedraui, Ingrid Soares de Souza, Andrey Alves Porto, Isabel Cristina Espósito Sorpreso, José Maria Soares, Juliana Zangirolami-Raimundo, David Matthew Garner, Rodrigo Daminello Raimundo · 2025 · Gynecological Endocrinology
  52. Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial
    R. Rosenson, Qinzhong Chen, Sherwin D. Najera, Martin L. Lee, D. Cho · 2018 · Cardiovascular Drugs and Therapy
  53. FACTORS ASSOCIATED WITH HYPERTENSION PREVALENCE AND CONTROL AMONG LEBANESE TYPE 2 DIABETIC PATIENTS
    Lama Soubra, Hanan Nureddin, Amal Galal Omar, Mounzer Saleh · 2016 · International Journal of Pharmacy and Pharmaceutical Sciences
  54. MRI-Derived Radiomics Features of Hepatic Fat Predict Metabolic States in Individuals without Cardiovascular Disease
    Daniel A.P. Gutmann, Susanne Rospleszcz, Wolfgang Rathmann, Christopher L. Schlett, Annette Peters, Christian Wachinger, Sergios Gatidis, Fabian Bamberg · 2020 · Academic Radiology
  55. Cost Effectiveness of Self-Monitoring of Blood Glucose (SMBG) for Patients with Type 2 Diabetes and Not on Insulin
    Sandra L. Tunis · 2011 · Applied Health Economics and Health Policy
  56. Diabetes and age-related demographic differences in risk factor control
    Brent M. Egan, Jiexiang Li, Tamara E. Wolfman, Angelo Sinopoli · 2014 · Journal of the American Society of Hypertension
  57. Relationships between the risk of cardiovascular disease in type 2 diabetes patients and both visit-to-visit variability and time-to-effect differences in blood pressure
    Toshiko Takao, Kumiko M. KIMURA, Machi Suka, Hiroyuki Yanagisawa, Masatoshi Kikuchi, Shoji Kawazu, Yutaka Matsuyama · 2015 · Journal of Diabetes and its Complications
  58. Hypertension and its management in countries in Africa and the Middle East, with special reference to the place ofβ-blockade
    Mohamad Samir Arnaout, Wael A. Almahmeed, Mohsen Ibrahim, James Ker, MA Khalil, Corrie T. Van Wyk, Giuseppe Mancia, Eyas Al Mousa · 2011 · Current Medical Research and Opinion
  59. The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
    Velimir Altabas, Jelena Marinković Radošević, Lucija Špoljarec, Stella Uremović, Tomislav Bulum · 2023 · Biomedicines
  60. Impact of continued high blood pressure on the progression of diabetic nephropathy after 10 years: KAMOGAWA-HBP study
    Shinnosuke Hata, Emi Ushigome, Yukako Hosomi, Takashi Yoshimura, Maya Takegami, Nobuko Kitagawa, Toru Tanaka, Goji Hasegawa, Masayoshi Ohnishi, Sei Tsunoda et al. · 2023 · Hypertension Research
  61. A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients
    José Antonio García‐Donaire, J. Segura, César Cerezo, Luis Miguel Ruilope · 2011 · Blood Pressure
  62. Pentosidina: un nuevo biomarcador de las complicaciones en la diabetes mellitus
    Sonia Morales, Jose Antonio Garcia-Salcedo, Manuel Muñoz‐Torres · 2010 · Medicina Clínica
  63. Predictors of all-cause and cardiovascular-specific mortality in type 2 diabetes: A competing risk modeling of an Iranian population
    Sahar Sadeghpour, Elham Faghihimani, Akbar Hassanzadeh, Masoud Amini, Marjan Mansourian · 2016 · Advanced Biomedical Research
  64. Threshold value of home pulse pressure predicting arterial stiffness in patients with type 2 diabetes: KAMOGAWA ‐ HBP study
    Noriyuki Kitagawa, Emi Ushigome, Shinobu Matsumoto, Chikako Oyabu, Hidetaka Ushigome, Isao Yokota, Mai Asano, Muhei Tanaka, Masahiro Yamazaki, Michiaki Fukui · 2018 · Journal of Clinical Hypertension
  65. Effect of Baseline Glycemic Level on Long-Term Cardiovascular Outcomes After Coronary Revascularization Therapy in Patients With Type 2 Diabetes Mellitus Treated With Hypoglycemic Agents
    Natsuhiko Ehara, Takeshi Morimoto, Yutaka Furukawa, Satoshi Shizuta, Ryoji Taniguchi, Yoshihisa Nakagawa, Kozo Hoshino, Naritatsu Saito, Takahiro Doi, Yoshisumi Haruna et al. · 2010 · The American Journal of Cardiology
  66. United Kingdom Prospective Diabetes Study Follow-Up Studies Establish a Legacy Effect of Therapy for Hyperglycemia but Not Hypertension
    David Charles Klonoff · 2008 · Journal of Diabetes Science and Technology
  67. Molecular Intricacies and the Role of ER Stress in Diabetes
    Muthuswamy Balasubramanyam, Lalit Pukhrambam Singh, Sampathkumar Rangasamy · 2012 · Experimental Diabetes Research
  68. Blood pressure lowering effects of β‐blockers as add‐on or combination therapy: A meta‐analysis of randomized controlled trials
    Qian‐Hui Guo, Zhiming Zhu, Yingqing Feng, Jinxiu Lin, Ji‐Guang Wang · 2023 · Journal of Clinical Hypertension
  69. Clinical significance of ‘cardiometabolic memory’: a systematic review of randomized controlled trials
    Hiroshi Itoh, Isao Kurihara, Kazutoshi Miyashita, Masami Tanaka · 2017 · Hypertension Research
  70. Are Corporations Re-Defining Illness and Health? The Diabetes Epidemic, Goal Numbers, and Blockbuster Drugs
    Linda M. Hunt, Elisabeth Arndt, Hannah S. Bell, Heather Howard · 2021 · Journal of Bioethical Inquiry
  71. Diabetes and the Cardiovascular System
    Darren K. McGuire · 2012 · Elsevier eBooks
  72. The effects of metformin on maternal haemodynamics in gestational diabetes mellitus: A pilot study
    Mohamed Waseem Osman, Mintu Nath, Asma A. Khalil, David R. Webb, Thompson Gordon Robinson, H. Mousa · 2018 · Diabetes Research and Clinical Practice
  73. Ameliorative impact of cold‐pressed Rosmarinus officinalis oil against liver toxicity and genotoxic effects in streptozotocin‐induced diabetic rats and their offspring
    Mohamed E. El‐Beeh, Maha Aljabri, Hisham F. Orabi, Sameer Hasan Qari, Mohamed Fawzy Ramadan · 2019 · Journal of Food Biochemistry · Retracted
  74. Efficacy and Safety of Switching Patients Inadequately Controlled on Basal Insulin to Insulin Glargine 300 U/mL: The TRANSITION 2 Study
    Pierre Gourdy, Amar Bahloul, Zahra Boultif, D. Gouet, Bruno Guerci · 2019 · Diabetes Therapy
  75. Linking diabetes and atherosclerosis
    Riccardo Candido, Stella Bernardi, Terri J. Allen · 2009 · Expert Review of Endocrinology & Metabolism
  76. Type 2 Diabetes in Older People; The Importance of Blood Pressure Control
    Ankur Jindal, Adam T. Whaley‐Connell, James R. Sowers · 2013 · Current Cardiovascular Risk Reports
  77. Time-to-effect relationships between systolic blood pressure and the risks of nephropathy and retinopathy in patients with type 2 diabetes
    Toshiko Takao, Yutaka Matsuyama, Machi Suka, Hiroyuki Yanagisawa, Masatoshi Kikuchi, Shoji Kawazu · 2014 · Journal of Diabetes and its Complications
  78. Glycaemic control and cardiovascular morbi-mortality: The contribution of the 2008 studies
    Christine Cugnet‐Anceau, Bernard Bauduceau · 2009 · Annales d Endocrinologie
  79. Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial
    Ali, Mohammed K., Singh, Kavita, Kondal, Dimple, Devarajan, Raji, Patel, Shivani A., Menon, V. Usha, Varthakavi, Premlata K., Vishwanathan, Vijay, Dharmalingam, Mala, Bantwal, Ganapati et al. · 2024 · PLOS Medicine
  80. Legacy in Cardiovascular Risk Factors Control: From Theory to Future Therapeutic Strategies?
    Lucie Pothen, Jean‐Luc Balligand · 2021 · Antioxidants
  81. brief history of the UK Prospective Diabetes Study: RURY R HOLMAN, FOR THE UKPDS GROUP
    Holman, Rury · 2022 · British Journal of Diabetes
  82. Legacy effect in combined diabetic-renal multifactorial intervention in patients with advanced diabetic nephropathy
    Jose Kuzhively, Bettina Tahsin, Peter Hart, Leon A. Fogelfeld · 2018 · Journal of Diabetes and its Complications
  83. A primer on metabolic memory: why existing diabesity treatments fail
    Sidar Çöpür, Peter R Rossing, Barış Afşar, Alan Alper Sag, Dimitrie Cristian Siriopol, Masanari Kuwabara, Alberto Ortíz, Mehmet Kanbay · 2020 · Clinical Kidney Journal
  84. A preliminary study of the relationship between general practice care and hospitalisation using a diabetes register, CARDIAB
    Elizabeth Jean Comino, Duong Thuy Tran, Jane Taggart, Siaw‐Teng Liaw, Warwick Ruscoe, Jill Snow, Mark Harris · 2013 · Australian Health Review
  85. Risk Markers for Atherothrombotic Disease
    Paul M. Ridker, Peter Libby · 2012 · Elsevier eBooks
  86. Organ memory: a key principle for understanding the pathophysiology of hypertension and other non-communicable diseases
    Hiroshi Itoh, Isao Kurihara, Kazutoshi Miyashita · 2018 · Hypertension Research
  87. Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: The KAMOGAWA‐HBP study
    Takuro Okamura, Emi Ushigome, Nobuko Kitagawa, Chikako Oyabu, Toru Tanaka, Goji Hasegawa, Naoto Nakamura, Masayoshi Ohnishi, Sei Tsunoda, Hidetaka Ushigome et al. · 2019 · Journal of Diabetes Investigation
  88. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS)
    Anoop Misra, Mayur Patel, Pankaj Agarwal, Sailesh Lodha, Nikhil Tandon, Mohan Magdum, Chittaranjan Sakerlal Yajnik, ROMIK GHOSH, Ajit Walekar · 2019 · Diabetes Technology & Therapeutics
  89. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension
    Eirik Olsen, Björn Holzhauer, Stevo Julius, Sverre Erik Kjeldsen, Anne Cecilie K. Larstorp, Giuseppe Mancia, Maria H. Mehlum, Rune Mo, Morten Rostrup, Camilla Lund Søraas et al. · 2021 · Blood Pressure
  90. Bariatric surgery: An IDF statement for obese Type 2 diabetes
    John B. Dixon, Paul Zimmet, K. G. M. M. Alberti, Francesco Rubino · 2011 · Obesity Research & Clinical Practice
  91. Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting
    Matteo Anselmino, Klas Malmberg, Linda Mellbin, Lars Rydén · 2010 · Reviews in Endocrine and Metabolic Disorders
  92. Nurse‐led clinics for strict hypertension control are effective long term: a 7 year follow‐up study
    A. Woodward, M Wallymahmed, John P.H. Wilding, Geoff V. Gill · 2010 · Diabetic Medicine
  93. Angiogenesis
    Nele Warmke, Andrew MN Walker, Richard M. Cubbon · 2017 · Elsevier eBooks
  94. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
    Cosentino, Francesco, Grant, Peter J, Aboyans, Victor, Bailey, Clifford J, Ceriello, Antonio, Delgado, Victoria, Federici, Massimo, Filippatos, Gerasimos, Grobbee, Diederick E, Hansen, Tina Birgitte et al. · 2020 · European Heart Journal
  95. Demographic and health factors associated with enrollment in posttrial studies: The women’s health initiative hormone therapy trials
    Mark Andrew Espeland, Mary B. Pettinger, Karen L. Falkner, Sally Ann Shumaker, Marian C. Limacher, Fridtjof Thomas, Kathryn E. Weaver, Marcia L. Stefanick, Cynthia McQuellon, Julie R. Hunt et al. · 2013 · Clinical Trials
  96. Obstructive sleep apnea is not associated with diabetic retinopathy in diabetes: a prospective case–control study
    Hind El Ouardighi, Kris Gustave Poppe, Pierre Kleynen, Lidia Grabzcan, Flora Veltri, Anne-Violette Bruyneel, Pham Anh Hong Nguyen, Marie Bruyneel · 2022 · Sleep And Breathing
  97. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison
    Nicolás Roberto Robles, Baldomero Romero, E. Fernández-Carbonero, Emilio Sanchez-Casado, Juan José Cubero · 2009 · Journal of the Renin-Angiotensin-Aldosterone System
  98. Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C
    NEIL SKOLNIK, Harmony Bonnes, H Yeh, Arie Katz · 2016 · Postgraduate Medicine
  99. Trends in the Care and Outcomes of Medicare Beneficiaries with Type 2 Diabetes, 2002–2011
    Kristen A. Hyland, Melissa A. Greiner, Laura Goettinger Qualls, Robert M. Califf, Adrian F. Hernandez, Lesley H. Curtis · 2016 · Endocrine Practice
  100. A TEN YEAR OVERVIEW OF SURGICAL AND INTERVENTIONAL ARRHYTHMOLOGY IN RUSSIA. SERVICE PECULIAR FEATURES IN THE FAR EAST
    С А Богачевская, Богачевский Александр Николаевич · 2017 · Social Aspects of Population Health